Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2011

Zauli Giorgio, Voltan Rebecca, Bosco Raffaella, Melloni Elisabetta, Marmiroli Sandra, Rigolin Gian Matteo, Cuneo Antonio, Secchiero Paola

Abstract excerpt

PURPOSE: To analyze the effect of the combination of Dasatinib, a multikinase inhibitor, plus Nutlin-3, a nongenotoxic activator of the p53 pathway, in primary B chronic lymphocytic leukemia (B-CLL) patient samples and B leukemic cell line models. EXPERIMENTAL DESIGN: The induction of cytotoxicity was evaluated in both primary B-CLL cell samples (n = 20) and in p53(wild-type) (EHEB, JVM-2) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Piperazines

Share to Proto-Oncogene Proteins c-akt

Share to Pyrimidines

Share to Thiazoles

Source

Identifiers

PMID: 21106726
DOI: 10.1158/1078-0432.CCR-10-2572

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.PMID 21106726Read ↗

Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.Semantic proximity Read ↗

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Semantic proximity Read ↗

The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.Semantic proximity Read ↗

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.Semantic proximity Read ↗

Recent Advances in the Therapeutic Perspectives of Nutlin-3Semantic proximity Read ↗

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patientsSemantic proximity Read ↗

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Semantic proximity Read ↗

Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.Semantic proximity Read ↗

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.Semantic proximity Read ↗

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screenSemantic proximity Read ↗

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsSemantic proximity Read ↗

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.